vWF is a multimeric glycoprotein that serves as the major carrier in plasma of Factor VIII (FVIII). We have used an anti-human vWF MAb W5-6A to investigate the FVIII binding site on vWF. W5-6A inhibited FVIII binding to vWFcoated polystyrene tubes in a concentration-dependent manner with 90% inhibition of FVIII binding at a concentration of 10 pg/ml. The W5-6A epitope was identified by screening a vWF fragment library using the bacteriophage expression vector Xgtll. DNA sequence analysis of 29 immunoreactive phage clones localized the W5-6A epitope to a nonadecapeptide spanning amino acid residues threonine 78 to threonine 96 at the amino-terminus of the mature vWF polypeptide. Purified fl-galactosidase/vWF fusion protein from one of these clones, vWF9, was incubated with radiolabeled W5-6A and caused near complete inhibition of W5-6A binding to vWFP. Inhibitory activity was lost after vWF9 trypsinization or reduction and alkylation. These data indicate that (a) the antigenic determinant recognized by W5-6A localizes to a nonadecapeptide at the NH2 terminus of the mature vWF polypeptide, (b) disulfide bonds within vWF9 may be necessary to maintain the structure required for immunoreactivity with W54A, and (c) W5-6A recognizes an immunogenic region on vWF that may be at (or near) the major FVIII binding domain.
Introduction
vWF and Factor VIII (FVIII)' are intimately related plasma glycoproteins with critical but distinct roles in the maintenance ofhemostatic integrity. vWF mediates platelet adhesion to subendothelial collagen in areas ofvessel wall injury (1) , and stabilizes FVIII in plasma by forming a noncovalently linked protein complex that is maintained by hydrophobic and electrostatic interactions (2, 3) . The ability of vWF to stabilize FVIII coagulant activity in plasma has been demonstrated in vitro (4) , and in cell culture using the recombinant form of FVIII (5) . Clinical observations in humans confirm the importance ofintact vWF in maintaining normal FVIII levels (6), and infusion studies in the dog using purified FVIII preparations demonstrate a marked loss of activity in the absence of endogenous vWF (7) . Although the stoichiometry of the vWF-FVIII macromolecular complex has not been clearly defined in humans, studies using the porcine model suggest the potential availability of -1 FVIII binding site per vWF monomer in steady-state plasma (8) .
Previous studies have made use of large vWF proteolytic fragments kD in size) to localize the vWF functional domains involved in binding to platelet glycoproteins Ib, IIB/ I11A, collagen, and heparin (reviewed in reference 9). Recently, a 272-amino acid proteolytic fragment from the amino-terminus of the mature vWF polypeptide has been demonstrated to contain the FVIII binding domain (10) . This is consistent with, and refines two subsequent reports localizing this site to the NH2-terminus of the mature vWF monomer (11, 12) .
To further study the molecular interaction between vWF and FVIII, we report here the characterization of an antihuman vWF MAb (W5-6A) that inhibits FVIII binding to vWF. We have screened a library of small vWF peptide fragments expressed as fusion proteins in Escherichia coli using the expression vector Xgtl 1 to precisely localize the antigenic determinant on vWF recognized by W5-6A. These data localize the epitope to a nonadecapeptide spanning amino acids threonine 78 to threonine 96 on the mature vWF polypeptide.
Methods
Immunoscreening the vWF recombinant library A vWF cDNA (13-16) fragment library in XgtlI was constructed as described by Mehra and Young (17) . Briefly, full-length vWF cDNA (13) was fragmented with DNAase I (Boehringer-Mannheim Biochemical, Indianapolis, IN), blunt-ended with T4 DNA polymerase (Boehringer-Mannheim Biochemical) and ligated to synthetic Eco RI linkers. vWF fragments in the size range of 200-500 bp were then ligated into the Eco RI site of the bacteriophage vector Xgtl 1. The library, containing -250,000 independent clones, should be sufficient to represent any given portion of the vWF protein 100-1,000 times (Ginsburg, D., and A. Yang, manuscript in preparation). Immunoscreening ofrecombinant phage was performed by the method of Young and Davis (18) , except that preincubation and antibody treatment of filters was performed in BLOTTO (BLOTTO is 5% Carnation nonfat powdered milk, 10 mM Tris, pH 7.5, 140 mM NaCl) (19).
W5-6A diluted 1:500 in BLOTTO was used to screen -200,000 clones. After washing, filters were incubated for 2 h in a 1:500 dilution ofan affinity-purified, peroxidase-tagged goat anti-mouse IgG (Cappel Laboratories, Malvern, PA), and developed by immersion in a sub-DNA sequencing andfusion protein (vWF9) preparation DNA from immunoreactive phage clones was purified from minilysates by standard methods (21) , or the vWF cDNA inserts amplified directly from single phage plaques or crude lysates via the polymerase chain reaction (PCR) (22) . Synthetic oligonucleotide primers beginning 69 bp upstream from the Eco RI cloning site (forward primer TGGCTGAATATCGACGGT'TT-CCAT) of Xgtl 1, and 79 bp downstream from the Eco RI site (reverse primer CAGACATGGCCT-GCCCGGTTATTA), were used for the PCR reaction. PCR conditions included a 1'15' denaturation step at 940C, a 1' 550C annealing step, and a 3' primer extension step at 720C. Amplifications consisted of 30 cycles using a DNA thermal cycler (Perkin-Elmer Cetus Corp., Norwalk, CT). Amplified cDNA insert sizes were determined by electrophoresis in an ethidium-stained 1.5% agarose gel, and PCR products were directly sequenced from both ends (across the Eco RI site) by a modification of the dideoxy chain termination method (23) using Sequenase (U.S. Biochemical Corporation, Cleveland, OH). The same oligonucleotides end-labeled with y-32P ATP (Amersham Corp., Arlington Heights, IL) (21) were used as sequencing primers. Sequences were localized within vWF by comparison to the full-length cDNA sequence (24) using the IBI-Pustell software package (International Biotechnologies, Inc., New Haven, CT) (25) . fl-Galactosidase-vWF fusion proteins from antibody-positive clones were prepared as previously described (19), and purified from crude E. coli lysates by passage over an anti-fl-galactosidase affinity column (Cappel Laboratories). Analysis by SDS-polyacrylamide gels (SDS-PAGE) (26) and Western blotting were performed using standard methods.
Competitive binding assays
Preparation ofvWF. Purified human vWF was prepared from cryoprecipitate by gel filtration chromatography (27) . Fractions containing ristocetin cofactor activity were isolated, pooled, and extensively dialyzed against 20 mM histidine, 100 mM sodium chloride, 5 mM calcium chloride, and 0.02% sodium azide. vWF was separated from FVIII by dissolving the complex in 0.05 M MES (4-morpholinoethane sulfonic acid), 0.25 M CaCl2, pH 7.5 and 5% (wt/vol) glycerol, followed by gel filtration in 4% agarose equilibrated with the same buffer. vWF containing fractions were then diluted to 1 U/ml (one unit is defined as ristocetin cofactor activity standardized against a pool of norman donors [28] ) in TBS-azide (10 mM Tris, pH 7.5, 140 mM NaCl, 0.02% sodium azide) and stored in 1-cm3 aliquots at -20°C.
Factor VIII. Recombinant Factor VIII (0.38 mg/ml, 1,780 U/ml) was the gift of Genetics Institute, Cambridge, MA.
Preparation of W5-6A. A panel of anti-human vWF MAb was prepared using standard hybridoma technology) (29). Commercial FVIII/vWF concentrate (Armour Pharmaceuticals, Kankakee, IL) was gel purified, and the vWF-containing fraction isolated by passage over a triethylaminoethyl cellulose column (Schleicher & Schuell, Keene, NH). This fraction was absorbed onto aluminum hydroxide, and used as the immunogen. Anti-vWF MAb were identified using 10% human plasma, and an affinity-purified '25I-radiolabeled rabbit anti-human vWF antibody. They were subsequently purified from murine ascitic fluid by protein A Sepharose (Pharmacia Fine Chemicals, Piscataway, NJ) chromatography (30 
Modification ofvWF9
Reduction and alkylation. The vWF9 fusion protein was diluted in 6M guanidinium chloride and 100 mM Tris, pH 8.5, and reduced under nitrogen at 37°C for 4.5 h with 32.5 mM DTT or under nitrogen at 24°C for 2 h with 12.8 mM 2-mercaptoethenol. Alkylation of the dithiothreitol-reduced sample was achieved with 65 mM iodoacetamide; the reaction was allowed to proceed for 20 min at 24°C in the dark before being quenched with 2-mercaptoethenol. Alternatively, the reduced sample was alkylated at 24°C for 2 h with 74 mM 4-vinyl pyridine, and both reaction mixtures were dialyzed against water and lyophilized.
Enzymatic modifications. Enzymatic cleavage of vWF9 was performed by dilution into or dialysis into 5% ammonium bicarbonate (250-500 Ml total volume). Enzyme was then added (10 
Results
Inhibition of FVIII/vWF binding by WS-6A. Competitive binding assays between '251-radiolabeled FVIII and vWFcoated polystyrene tubes were carried out for a number of MAbs, and results are conveniently reported as percent inhibition, as calculated above. W5-6A inhibited binding in a concentration-dependent manner, resulting in 52% reduction of FVIII binding at 1 gg/ml and 90% reduction at 10 ,ug/ml (Fig.   1 ). Maximal '251I-radiolabeled FVIII binding (no ligand) was 2,140±32 cpm and background '251-radiolabeled FVIII (no vWF) was 72±12 cpm. Specific counts for W5-6A were 1,702±70 (0.1 Mg), 993±18 (1 ug), and 218±23 cpm (10Mg). In the same competition assay a second anti-human vWF MAb (W5-5) and an anti-human Factor IX antibody (40D1 1) both showed minimal inhibitory activity at concentrations up to 10 Mg/ml. Fab fragments were prepared from W5-6A and evaluated in the same competition assay. A similar pattern of concentration-dependent inhibition was seen. To further characterize the antigenic site recognized by W5-6A, the vWF9 fusion protein was incubated with '25I-W5-6A and binding to vWF-coated polystyrene tubes was assayed. As determined by competition assays, undiluted extracts of vWF9 inhibited binding 13-fold when compared with pooled normal plasma (data not shown). However, vWF9 maintained > 90% inhibition at a 1,000-fold dilution of the fusion protein (Fig. 4) (33) . Less is known about the regulation of FVIII secretion, although recent evidence suggests that the primary site of synthesis is the hepatocyte (34) . Both in vivo and in vitro evidence confirm the necessary role ofvWF in maintaining FVIII stability (4-7).
An anti-human FVIII MAb has been described that inhibits binding of FVIII to vWF (35 (39) which may be inadequately carried out in this bacterial expression system. The estimation ofvWF9 concentration in the extract is -1 mg/ml, as judged by comparison to a known ,B-galactosidase standard (Sigma Chemical Co., St. Louis, MO) (data not shown). This would be -100-fold the concentration An Anti-von Willebrand Factor Antibody Inhibiting Factor VIII Binding 59 N, 'I, ofplasmatic vWF (10 ,g/ml), further suggesting that the above interactive limitations may affect the functional efficacy of the fusion protein.
Acquired or congenital defects in the vWF/FVIII. interaction may be implicated in the pathogenesis of several clinical disorders. Montgomery and colleagues (40) have described a pedigree with an autosomal dominant disease manifest as a mild bleeding disorder with abnormal FVIII coagulant activity. They have suggested that this would be consistent with a vWF variant caused by defective binding of FVIII. It would be ofinterest to determine ifthe molecular defect in such patients was due to an abnormality in the region of our nonadecapeptide. In addition to the frequent development of FVIII alloantibodies in patients with severe hemophilia (41), spontaneously occurring autoantibodies to FVIII may also occur, leading to a severe hemorrhagic disorder with potentially grave sequelae (42). Gawryl and. Hoyer have suggested that a subclass of such antibodies may inactivate FVIII by interfering with the vWF/FVIII interactive site (43) . Although the development of allo-or autoantibodies to vWF is a rare occurrence (44) , no such antibodies have been described with similar characteristics. Further refinement of the structural requirements involved in the vWF/FVIII interaction may improve our understanding of these clinical disorders, and have implications for the biology of both vWF and FVIII function. Finally, by studying reagents designed to interfere with this binding interaction, clinically useful drugs may eventually be developed for their potential use as anticoagulant agents.
